Daming Zhu

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint A quantitative slot blot assay for host cell protein impurities in recombinant proteins expressed in E. coli
    Daming Zhu
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    J Immunol Methods 306:40-50. 2005
  2. pmc Development of a Direct Alhydrogel Formulation Immunoassay (DAFIA)
    Daming Zhu
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville, MD 20852, USA
    J Immunol Methods 344:73-8. 2009
  3. pmc Determination of protein concentration for protein-protein conjugates using ultraviolet absorption
    Daming Zhu
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    J Immunol Methods 387:317-21. 2013
  4. pmc Efficient extraction of vaccines formulated in aluminum hydroxide gel by including surfactants in the extraction buffer
    Daming Zhu
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    Vaccine 30:189-94. 2012
  5. pmc Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine
    Daming Zhu
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Disease, National Institutes of Health, 5640 Fishers Lane, Rockville, MD 20852, USA
    Vaccine 29:3640-5. 2011
  6. pmc Use of o-phthalaldehyde assay to determine protein contents of Alhydrogel-based vaccines
    Daming Zhu
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Disease, National Institutes of Health, 5640 Fishers Lane, Rockville, MD 20852, USA
    Vaccine 27:6054-9. 2009
  7. pmc Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults
    Mark A Pierce
    Malaria Vaccine Development Branch MVDB, National Institute of Allergy and Infectious Disease, National Institutes of Health NIAID NIH, Rockville, MD 20852, United States
    Vaccine 28:2236-42. 2010
  8. pmc Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria
    Ruth D Ellis
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIAID NIH, Rockville, Maryland, United States of America
    PLoS ONE 7:e46094. 2012
  9. pmc Immunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1
    Feng Qian
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America
    PLoS ONE 7:e36996. 2012
  10. ncbi request reprint Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations
    Aaron P Miles
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Twinbrook I Room 1118, Rockville, MD 20852, USA
    Vaccine 23:2530-9. 2005

Collaborators

Detail Information

Publications17

  1. ncbi request reprint A quantitative slot blot assay for host cell protein impurities in recombinant proteins expressed in E. coli
    Daming Zhu
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    J Immunol Methods 306:40-50. 2005
    ..This assay proved simple yet very sensitive and accurate, giving highly reproducible results. Thus it is suitable for evaluating host cell protein levels in clinical grade recombinant proteins expressed in E. coli...
  2. pmc Development of a Direct Alhydrogel Formulation Immunoassay (DAFIA)
    Daming Zhu
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville, MD 20852, USA
    J Immunol Methods 344:73-8. 2009
    ....
  3. pmc Determination of protein concentration for protein-protein conjugates using ultraviolet absorption
    Daming Zhu
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    J Immunol Methods 387:317-21. 2013
    ..The accuracy of the method was verified using mixtures of known proteins. The present study provides a rapid, simple and accurate method for determining protein concentration in protein-protein conjugates...
  4. pmc Efficient extraction of vaccines formulated in aluminum hydroxide gel by including surfactants in the extraction buffer
    Daming Zhu
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    Vaccine 30:189-94. 2012
    ..The results showed that inclusion of SDS or cetylpyridinium chloride in extraction buffer increased the antigen recovery dramatically and can be used for efficient characterization of Alhydrogel vaccines...
  5. pmc Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine
    Daming Zhu
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Disease, National Institutes of Health, 5640 Fishers Lane, Rockville, MD 20852, USA
    Vaccine 29:3640-5. 2011
    ..The results of the present study indicate that the AMA1-C1/ISA 720 emulsion was unstable after 12 months of storage, after which AMA1-C1 proteins were partially degraded...
  6. pmc Use of o-phthalaldehyde assay to determine protein contents of Alhydrogel-based vaccines
    Daming Zhu
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Disease, National Institutes of Health, 5640 Fishers Lane, Rockville, MD 20852, USA
    Vaccine 27:6054-9. 2009
    ..25-500 microg/mL). This assay has proven to be highly useful in our laboratory and been used in routine vaccine quality control processes...
  7. pmc Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults
    Mark A Pierce
    Malaria Vaccine Development Branch MVDB, National Institute of Allergy and Infectious Disease, National Institutes of Health NIAID NIH, Rockville, MD 20852, United States
    Vaccine 28:2236-42. 2010
    ..AMA1-C1 formulated in ISA 720 is immunogenic in malaria-naïve Australian adults. It is reasonably tolerated, though some transient, severe, and late local reactions are seen...
  8. pmc Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria
    Ruth D Ellis
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health NIAID NIH, Rockville, Maryland, United States of America
    PLoS ONE 7:e46094. 2012
    ..In vitro growth inhibition was demonstrated and was closely correlated with anti-AMA1 antibody responses. A Phase 1b trial in malaria-exposed adults is being conducted. Trial registration: Clinicaltrials.gov NCT00889616...
  9. pmc Immunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1
    Feng Qian
    Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America
    PLoS ONE 7:e36996. 2012
    ..Clearly, enhancing the immunogenicity of a recombinant protein vaccine candidate by the formation of protein complexes must be established on an empirical basis...
  10. ncbi request reprint Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations
    Aaron P Miles
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Twinbrook I Room 1118, Rockville, MD 20852, USA
    Vaccine 23:2530-9. 2005
    ....
  11. pmc Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria
    Gregory E D Mullen
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America
    PLoS ONE 3:e2940. 2008
    ..This is the first reported use in humans of an investigational vaccine, AMA1-C1/Alhydrogel, with the novel adjuvant CPG 7909...
  12. pmc Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults
    Ruth D Ellis
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases National Institutes of Health, Rockville, Maryland, USA
    PLoS ONE 5:e8787. 2010
    ..To improve the level of antibody response, MSP1(42)-C1 was formulated with Alhydrogel plus the novel adjuvant CPG 7909...
  13. pmc Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51
    Yimin Wu
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, United States of America
    PLoS ONE 3:e2636. 2008
    ..This single blinded, dose escalating, controlled Phase 1 study assessed the safety and immunogenicity of recombinant Pfs25 and Pvs25 formulated with Montanide ISA 51, a water-in-oil emulsion...
  14. pmc Enhanced antibody responses to Plasmodium falciparum Pfs28 induced in mice by conjugation to ExoProtein A of Pseudomonas aeruginosa with an improved procedure
    Feng Qian
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
    Microbes Infect 11:408-12. 2009
    ..A significant increase in immunogenicity measured by ELISA was observed in mice immunized with conjugated Pfs28 as compared to unconjugated Pfs28...
  15. ncbi request reprint Determining residual host cell antigen levels in purified recombinant proteins by slot blot and scanning laser densitometry
    Aaron P Miles
    Biochemical Assay Development and Quality Control, Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA
    Methods Mol Biol 308:233-42. 2005
  16. pmc N-methyl-D-aspartate and TrkB receptors protect neurons against glutamate excitotoxicity through an extracellular signal-regulated kinase pathway
    Daming Zhu
    Department of Neurology and Neuroscience, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA
    J Neurosci Res 80:104-13. 2005
    ..By increasing antiapoptotic proteins of the Bcl-2 family, NMDA receptor activation may also promote neuronal survival by preventing apoptosis...
  17. ncbi request reprint AMPA protects cultured neurons against glutamate excitotoxicity through a phosphatidylinositol 3-kinase-dependent activation in extracellular signal-regulated kinase to upregulate BDNF gene expression
    Xuan Wu
    Department of Neurology and Neuroscience, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
    J Neurochem 90:807-18. 2004
    ..Thus, AMPA receptors protect neurons through a mechanism involving BDNF release, TrkB receptor activation, and a signaling pathway involving a PI3-K dependent activation of MAPK that increases BDNF expression...